Home / Merck & CO INC. (MRK) / rescue medications
Forward catalyst · MRK

rescue medications

Sponsor Merck & CO INC. · listed as MRK

READOUT Phase 3 Confidence: medium Source: clinicaltrials

rescue medications is a clinical-stage drug asset sponsored by Merck & CO INC., listed as MRK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jan 4, 2027 (day precision, medium confidence), tied to trial NCT06356311. The asset is in Phase 3 and currently active not recruiting, studied in Gastroesophageal Cancer. It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-01-04
As disclosedJan 4, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06356311
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorMerck Sharp & Dohme LLC
Listed asMRK
Condition(s)Gastroesophageal Cancer
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More MRK catalysts